Established in 2013, Stem Sel develops innovative and efficient methods to select stem cells for applications in regenerative medicine.
At the moment, the company focuses on prototype development, engineering, production and commercialisation of Celector® and other related consumables designed to select and sort human stem cells from adult “discarded” tissues - umbilical cords and placental sources to milky teeth – and use them to reconstruct damaged tissues.
The competitive advantage of Celector lies in its ability to sort and select stem cells without any cell manipulation. This process not only circumvents regulatory restrictions but it is also one of the most efficient stem cells sorting methods on the market.
The product can also be used in laboratories that produce stem cells for therapies and cellular transplants.
Stem Sel cooperates with the University of Bologna for the development of new cellular selection technologies. It also collaborates with the Bologna orthopedics Rizzoli Institute and ReMembrane SRL for validation and cellular application developments, and with the Oncology Scientific Institute in Meldola, Forlì.
The spin-off won the 2012 edition of the StartCup business plan competition, supported by the Emilia-Romagna Region and the UK-Italy Business Award, sponsored by the British Embassy in Rome for innovation and internationalization.
The Gaetano Marzotto prize supports innovative companies that are able to generate positive societal spillovers. The winner will be announced on 27 November 2014 and will receive a €300.000 cash prize, plus €25.000 worth of consulting.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
